Targeting the PI3K Signaling Pathway in Cancer

Overview

Journal Curr Opin Genet Dev

Publisher Elsevier

Specialties Biology
Genetics

Date 2009 Dec 17

PMID 20006486

Citations 282

Authors

Kwok-Kin Wong

Jeffrey A Engelman

Lewis C Cantley

Affiliations

Soon will be listed here.

Abstract

The phosphoinositide 3-kinase (PI3K) pathway is activated in a variety of different human cancers, and inhibitors of this pathway are under active development as anti-cancer therapeutics. In this review, we discuss the data supporting the use of PI3K pathway inhibitors in genetically and clinically defined cancers. This review focuses on their efficacy as single agents and in combination with other targeted therapies, specifically those targeting the MEK-ERK signaling pathway.

Citing Articles

Synergistic Effects of the Combination of Alpelisib (PI3K Inhibitor) and Ribociclib (CDK4/6 Inhibitor) in Preclinical Colorectal Cancer Models.

Aslam R, Richards C, Fay J, Hudson L, Workman J, Lee C Int J Mol Sci. 2025; 25(24.

PMID: 39769028 PMC: 11676898. DOI: 10.3390/ijms252413264.

Linking Phosphoinositides to Proteins: A Novel Signaling PIPeline.

Carrillo N, Awasthi P, Lee J, Wen T, Chen M, Sterling C J Cell Signal. 2024; 5(3):114-121.

PMID: 39582486 PMC: 11584056. DOI: 10.33696/signaling.5.118.

MTHFD1 Regulates Autophagy to Promote Growth and Metastasis in Colorectal Cancer via the PI3K-AKT-mTOR Signaling Pathway.

Li Z, Ke H, Cai J, Ye S, Huang J, Zhang C Cancer Med. 2024; 13(22):e70267.

PMID: 39571599 PMC: 11581708. DOI: 10.1002/cam4.70267.

How lactate affects immune strategies in lymphoma.

Zhou Y, Lou J, Tian Y, Ding J, Wang X, Tang B Front Mol Biosci. 2024; 11:1480884.

PMID: 39464313 PMC: 11502318. DOI: 10.3389/fmolb.2024.1480884.

Competing endogenous RNAs regulatory crosstalk networks: The messages from the RNA world to signaling pathways directing cancer stem cell development.

Aria H, Azizi M, Nazem S, Mansoori B, Darbeheshti F, Niazmand A Heliyon. 2024; 10(15):e35208.

PMID: 39170516 PMC: 11337742. DOI: 10.1016/j.heliyon.2024.e35208.

References

Yun C, Mengwasser K, Toms A, Woo M, Greulich H, Wong K . The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008; 105(6):2070-5. PMC: 2538882. DOI: 10.1073/pnas.0709662105. View

Samuels Y, Velculescu V . Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004; 3(10):1221-4. DOI: 10.4161/cc.3.10.1164. View

Mirzoeva O, Das D, Heiser L, Bhattacharya S, Siwak D, Gendelman R . Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 2009; 69(2):565-72. PMC: 2737189. DOI: 10.1158/0008-5472.CAN-08-3389. View

Vasudevan K, Barbie D, Davies M, Rabinovsky R, McNear C, Kim J . AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009; 16(1):21-32. PMC: 2752826. DOI: 10.1016/j.ccr.2009.04.012. View

Engelman J . Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9(8):550-62. DOI: 10.1038/nrc2664. View

Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang S . PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997; 275(5308):1943-7. DOI: 10.1126/science.275.5308.1943. View

Yuan T, Cantley L . PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008; 27(41):5497-510. PMC: 3398461. DOI: 10.1038/onc.2008.245. View

Sos M, Fischer S, Ullrich R, Peifer M, Heuckmann J, Koker M . Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A. 2009; 106(43):18351-6. PMC: 2757399. DOI: 10.1073/pnas.0907325106. View

Gupta S, Ramjaun A, Haiko P, Wang Y, Warne P, Nicke B . Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell. 2007; 129(5):957-68. DOI: 10.1016/j.cell.2007.03.051. View

10.

Junttila T, Akita R, Parsons K, Fields C, Lewis Phillips G, Friedman L . Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009; 15(5):429-40. DOI: 10.1016/j.ccr.2009.03.020. View

11.

Guix M, Faber A, Wang S, Olivares M, Song Y, Qu S . Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest. 2008; 118(7):2609-19. PMC: 2430495. DOI: 10.1172/JCI34588. View

12.

Ihle N, Lemos Jr R, Wipf P, Yacoub A, Mitchell C, Siwak D . Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 2009; 69(1):143-50. PMC: 2613546. DOI: 10.1158/0008-5472.CAN-07-6656. View

13.

Bean J, Brennan C, Shih J, Riely G, Viale A, Wang L . MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007; 104(52):20932-7. PMC: 2409244. DOI: 10.1073/pnas.0710370104. View

14.

Sergina N, Rausch M, Wang D, Blair J, Hann B, Shokat K . Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007; 445(7126):437-41. PMC: 3025857. DOI: 10.1038/nature05474. View

15.

Samuels Y, Ericson K . Oncogenic PI3K and its role in cancer. Curr Opin Oncol. 2005; 18(1):77-82. DOI: 10.1097/01.cco.0000198021.99347.b9. View

16.

Samuels Y, Diaz Jr L, Schmidt-Kittler O, Cummins J, Delong L, Cheong I . Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005; 7(6):561-73. DOI: 10.1016/j.ccr.2005.05.014. View

17.

Engelman J, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park J . MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316(5827):1039-43. DOI: 10.1126/science.1141478. View

18.

Costa D, Halmos B, Kumar A, Schumer S, Huberman M, Boggon T . BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 2007; 4(10):1669-79. PMC: 2043012. DOI: 10.1371/journal.pmed.0040315. View

19.

Isakoff S, Engelman J, Irie H, Luo J, Brachmann S, Pearline R . Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005; 65(23):10992-1000. DOI: 10.1158/0008-5472.CAN-05-2612. View

20.

Vivanco I, Sawyers C . The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7):489-501. DOI: 10.1038/nrc839. View